Therapeutics and Diagnostics for Women's Disorders

Published by: BCC Research

Published: Mar. 1, 2009 - 195 Pages

Table of Contents

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

METHODOLOGY

RELATED BCC STUDIES

ANALYSTS CREDENTIALS

BCC RESEARCH ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE U.S. MARKET FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, THROUGH 2013 ($ MILLIONS)

SUMMARY FIGURE U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, 2006-2013 ($ MILLIONS)

CHAPTER THREE: INDUSTRY OVERVIEW

DEFINITION OF WOMEN’S DISORDERS

IMPORTANCE OF THE INDUSTRY AND DEMOGRAPHICS

TABLE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)

FIGURE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)

TABLE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)

FIGURE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)

TABLE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)

FIGURE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)

HISTORY OF THE INDUSTRY AND RESPONSE TO WOMEN’S HEALTHCARE NEEDS

REGULATORY ENVIRONMENT

EFFECTS OF AGING

FIGURE 4 FEMALE LIKELIHOOD OF GETTING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2008 (%)

CONTRACEPTIVE INSURANCE COVERAGE

TABLE 4 INSURANCE COVERAGE OF CONTRACEPTIVES BY STATE

CONTRACEPTIVE USE IN TEENS INCREASES

NEW USE FOR CONTRACEPTIVES

AGING AND INFERTILITY

CONTRACEPTIVE PATCH LINKED TO DEATHS

WOMEN AND SEXUAL HEALTH

INCIDENCE OF SEXUAL DYSFUNCTION

VASCULAR TREATMENTS AND SEXUAL DYSFUNCTION

DIAGNOSTICS

NEW DEVELOPMENTS IN SEXUAL DYSFUNCTION TREATMENTS FOR WOMEN

Alista

TABLE 5 U.S. SEXUAL DYSFUNCTION PRODUCTS FOR WOMEN IN DEVELOPMENT, 2008

SEXUAL DYSFUNCTION IN CANCER

INFERTILITY AND CANCER

CHEMOTHERAPY

RADIATION

PREVENTION STRATEGIES

MARKETING AND WOMEN

COUNTERFEIT PHARMACEUTICALS

GENERIC PARTICIPATION

TABLE 6 U.S. PRESCRIPTION GENERIC DRUG APPROVALS FOR CONSTRACEPTION BY COMPANY AND APPROVAL DATE, 2003-2008

INTERNATIONAL ISSUES

CHAPTER FOUR: AUTOIMMUNE DISEASES

U.S. MARKET OVERVIEW

MARKET SIZE

TABLE 7 U.S. MARKET FORECAST FOR AUTOIMMUNE DISEASES BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 8 MANUFACTURERS OF AUTOIMMUNE DISEASE PRODUCTS, 2008

TABLE 9 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)

FIGURE 5 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 (%)

MARKET BY DISEASE TYPE

CHRONIC FATIGUE SYNDROME

Incidence and Mortality

Market Indicators

FIBROMYALGIA

Incidence

Diagnostics

Pain in 11 of 18 Tender Point Sites on Digital Palpation

Market Indicators

Current Market Participants

MYASTHENIA GRAVIS

Incidence and Mortality

Diagnostics

Market Indicators

Current Market Participants

SJOGREN’S SYNDROME

Incidence and Mortality

Diagnostics

Market Indicators

Current Market Participants

SYSTEMIC LUPUS ERYTHEMATOSUS

Incidence and Mortality

Diagnostics

Market Indicators

IN DEVELOPMENT

PRESTARA

AMPLIGEN

RIQUENT

ALL U.S. PRODUCTS IN DEVELOPMENT

TABLE 10 U.S. AUTOIMMUNE DISEASE PRODUCTS IN DEVELOPMENT, 2008

CHAPTER FIVE: WOMEN’S CANCERS

U.S. MARKET OVERVIEW

MARKET SIZE

TABLE 11 U.S. MARKET FORECAST FOR WOMEN’S CANCER BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 12 MANUFACTURERS OF WOMEN’S CANCER PRODUCTS, 2008

TABLE 13 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)

FIGURE 6 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 (%)

MARKET BY TYPE OF CANCER

BREAST CANCER

TABLE 14 TNM CLASSIFICATIONS OF BREAST CANCERS

TABLE 15 5-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2008 (%)

Incidence and Mortality

TABLE 16 TOTAL YEARLY CASES AND DEATHS FOR BREAST CANCER IN WOMEN WORLDWIDE, 2008

Diagnostics

Market Indicators

Current Market Participants

CERVICAL CANCER

Incidence and Mortality

Diagnostics

Market Indicators

Current Market Participants

ENDOMETRIAL CANCER

Incidence and Mortality

Market Indicators

Current Market Participants

OVARIAN CANCER

Incidence and Mortality

Diagnostics

Market Indicators

Market Indicators (Continued)

Current Market Participants

IN DEVELOPMENT

572016

ACTIMMUNE

ARZOXIFENE

ATAMESTANE

FASLODEX

IMC-C2259

FABLYN

OVAREX

TEMSIROLIMUS

THERATOPE

OPAXIO

A FEW SELECT U.S. PRODUCTS IN DEVELOPMENT

TABLE 17 SELECTED WOMEN’S CANCER PRODUCTS IN DEVELOPMENT IN THE U.S., 2008

CHAPTER SIX: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

U.S. MARKET OVERVIEW

TABLE 18 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS

MARKET SIZE

TABLE 19 U.S. MARKET FORECAST FOR GYNECOLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 20 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

FIGURE 7 SUMMARY OF U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUES, 2008 (%)

TABLE 21 MANUFACTURERS OF GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS, 2008

MARKET BY DISEASE TYPE

BACTERIAL VAGINOSIS

Incidence

Market Indicators

CANDIDIASIS

Incidence

Market Indicators

Current Market Participants

CERVICAL DYSPLASIA

Incidence

CHLAMYDIA

Incidence

Diagnostics

Market Indicators

CONDYLOMA

Incidence

Market Indicators

DYSMENORRHEA

Incidence

ENDOMETRIOSIS

Incidence

Market Indicators

FIBROIDS

Incidence

Market Indicators

GENITAL HERPES

Incidence

Diagnostics

Market Indicators

Current Market Participants

PELVIC INFLAMMATORY DISEASE

Incidence

Market Indicators

IN DEVELOPMENT

HUMAN PAPILLOMAVIRUS

LOW DOSE ORAL INTERFERON-ALPHA

ALL U.S. PRODUCTS IN DEVELOPMENT

TABLE 22 GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS IN DEVELOPMENT IN THE U.S., 2008

CHAPTER SEVEN: KIDNEY AND UROLOGIC DISEASES AND CONDITIONS

U.S. MARKET OVERVIEW

MARKET SIZE

TABLE 23 U.S. MARKET FORECAST FOR KIDNEY AND UROLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 24 U.S. KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

FIGURE 8 SUMMARY OF KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUES, 2008 (%)

TABLE 25 MANUFACTURERS OF KIDNEY AND UROLOGIC DISEASE AND CONDITION PRODUCTS, 2008

MARKET BY DISEASE TYPE

URINARY TRACT INFECTIONS

Incidence

Diagnostics

Market Indicators

URINARY INCONTINENCE

Incidence

Market Indicators

Current Market Participants

TABLE 26 U.S. URINARY INCONTINENCE/OVERACTIVE BLADDER MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

URINARY INTERSTITIAL CYSTITIS

Incidence

Market Size and Growth

IN DEVELOPMENT

ALL U.S. PRODUCTS IN DEVELOPMENT

TABLE 27 KIDNEY AND UROLOGICAL DISEASE AND CONDITIONS PRODUCTS IN DEVELOPMENT IN THE U.S., 2008

CHAPTER EIGHT: REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS

U.S. MARKET OVERVIEW

MARKET SIZE

TABLE 28 U.S. MARKET FORECAST FOR REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 29 U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

FIGURE 9 SUMMARY OF U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUES, 2008 (%)

MARKET BY TYPE

CONTRACEPTION

TABLE 30 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)

FIGURE 10 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)

Market Indicators

Most Commonly Used Oral Contraceptives

TABLE 31 MOST COMMONLY USED ORAL CONTRACEPTIVES IN THE U.S., 2008 D)

Current Market Participants

TABLE 32 U.S. CONTRACEPTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

INFERTILITY

Incidence

Market Indicators

Hormonal Therapy

Surgical Treatment

Artificial Insemination

Assisted Reproductive Technology

Current Market Participants

TABLE 33 U.S. INFERTILITY MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

MENOPAUSE

Incidence

Market Indicators

Most Commonly Used Menopause Treatment Products

TABLE 34 MOST COMMONLY USED MENOPAUSE TREATMENT PRODUCTS 2008

Current Market Participants

TABLE 35 U.S. MENOPAUSE MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

IN DEVELOPMENT

BAZEDOXIFENE/CONJUGATED ESTROGENS

ALL U.S. PRODUCTS IN DEVELOPMENT

TABLE 36 REPRODUCTIVE-RELATED PRODUCTS IN DEVELOPMENT IN THE U.S., 2008

CHAPTER NINE: RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

U.S. MARKET OVERVIEW

MARKET SIZE

TABLE 37 U.S. MARKET FORECAST FOR RHEUMATOID ARTHRITIS AND OSTEOPOROSIS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 38 U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

FIGURE 11 SUMMARY OF U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUES, 2008 (%)

TABLE 39 MANUFACTURERS OF RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS, 2008

MARKET BY TYPE

RHEUMATOID ARTHRITIS

Incidence

Market Indicators

Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs

Cox-2 Inhibitors

Disease-Modifying Anti-Rheumatic Drugs

Immunosuppressants

Corticosteroids

Tumor Necrosis Factor Blocker

B-lymphocyte-Restricted Differentiation Antigen (CD20) Inhibitor

Selective Costimulation Modulator

Current Market Participants

TABLE 40 U.S. RHEUMATOID ARTHRITIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

OSTEOPOROSIS

Incidence

Diagnostics

Market Indicators

Current Market Participants

TABLE 41 U.S. OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)

IN DEVELOPMENT

PREXIGE

REMICADE

PREOS

ARZOXIFENE

FABLYN

U.S. PRODUCTS IN DEVELOPMENT

TABLE 42 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS IN DEVELOPMENT IN U.S., 2008

CHAPTER TEN: MARKET SUMMARY

U.S. WOMEN’S HEALTHCARE MARKET ANALYSIS

TABLE 43 U.S. WOMEN’S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)

FIGURE 12 U.S. WOMEN’S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)

CHAPTER ELEVEN: INDUSTRY PARTICIPANTS BY TYPE

TABLE 44 MAJOR WOMEN’S HEALTHCARE INDUSTRY PARTICIPANTS, BY PRODUCT TYPE, 2008

SELECTED COMPANY PROFILES

ASTRAZENECA

BARR LABORATORIES, INC.

BRISTOL-MYERS SQUIBB CO.

ELI LILLY & CO.

GENENTECH

GLAXOSMITHKLINE

MERCK & CO., INC.

ORTHO-MCNEIL PHARMACEUTICALS

PFIZER

SERONO INTERNATIONAL S.A.

WYETH

LIST OF COMPANIES

Abstract

This Report:

• Covers a wide variety of products and disorders that predominantly affect women including autoimmune diseases, women’s cancer, gynecological infections and diseases, reproductive-related therapies and diagnostics, rheumatoid arthritis and osteoporosis
• Includes U.S. market forecasts for therapeutics and diagnostics for women’s disorders through 2014
• Provides detailed information based on product categories and their use
• Discusses new therapeutics and diagnostics that have emerged and have a significant impact on women’s health
• Profiles leading companies.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.